Background Initiation of efavirenz is commonly associated with sleep disturbances.
Assessment of sleep using the electroencephalogram and electromyogram enables sleep …

Abstract Papua New Guinea (PNG) has a high HIV/AIDS prevalence and very high
frequency of the CYP2B6 c. 516G> T (rs3745274) variant. We have conducted the first …

Non‐nucleoside reverse transcriptase inhibitors are important antiretroviral agents for the
treatment of human immunodeficiency virus. Some non‐nucleoside reverse transcriptase …

Importance of the field: The use of the first generation non-nucleoside reverse transcriptase
inhibitor efavirenz (EFV) as a component of first-line antiretroviral therapy has been …

Objectives The main aim of this study was to investigate the effect of CYP2B6 gene
polymorphisms on efavirenz (EFV) plasma concentrations in Han Chinese patients with …

Efavirenz is a non-nucleoside reverse transcriptase inhibitor used as first-line therapy for the
treatment of HIV infection. Cytochrome P450 (CYP) CYP2B6 G516T (rs3745274) is a well …

Efavirenz (EFV) is metabolized by cytochrome P450 2B6 (CYP2B6) in the liver. We analyzed
the genotypes of CYP2B6 and their contribution to plasma EFV concentrations in 35 EFV …

A 48-year-old Caucasian male patient presented with severe adverse drug events (ADEs)
while being treated with a standard dose (600 mg/day) of efavirenz. The patient's clinical …

Abstract Background Cytochrome P450 2B6 (CYP2B6) metabolizes efavirenz and
nevirapine, the major core antiretroviral drugs for HIV in Thailand. Rifampicin, a critical …

The prevalence of the 516 G> T polymorphism of the CYP2B6 gene and its influence on
steady-state plasma efavirenz and nevirapine concentrations in HIV-infected patients in …